Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213056 | 0.84 | IKBKB (0.60) | IKBKBJUNMAPK8MAPK9HDAC6 | |
| SCHEMBL5213069 | 0.81 | HDAC2 (0.42) | IKBKBHDAC2PKMJUNMAPK8 | |
| SCHEMBL4092080 | 0.77 | IKBKB (0.67) | IKBKB | |
| SCHEMBL1385637 | 0.76 | IKBKB (0.65) | IKBKBMAPT | |
| SCHEMBL5211200 | 0.76 | IKBKB (0.65) | IKBKBHDAC2CDC7 | |
| SCHEMBL1382301 | 0.75 | IKBKB (1.00) | IKBKBMAPT | |
| SCHEMBL1385872 | 0.74 | IKBKB (0.67) | IKBKBHDAC2HDAC3HDAC1NPC1 | |
| SCHEMBL6586102 | 0.74 | PKM (0.72) | HDAC2PKMJUNMAPK8MAPK9 | |
| SCHEMBL1826459 | 0.73 | CDC7 (0.51) | IKBKBHDAC2PKMJUNMAPK8 | |
| SCHEMBL1383955 | 0.73 | IKBKB (0.82) | IKBKBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | claimed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | claimed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | claimed |
| CN-1538968-A | Novel compounds | — | 2004-10-20 | — | — | CN | claimed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | claimed |
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| CN-1538968-A | Novel compounds | — | 2004-10-20 | — | — | CN | disclosed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | IKBKB 2823/4885HDAC2 273/4885PKM 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.